There is currently no accepted biomarker for assessing response to treatment in patients with bone disease from advanced prostate cancer (APC). Whole-Body Diffusion-Weighted-MRI (WBDWI) is emerging as a bone response biomarker in APC. However, automatic segmentation of disease from WBDWI is needed to quantify changes in WBDWI-derived biomarkers (global tumour apparent diffusion coefficient (gADC) and total tumour volume, tDV) for more reliable response assessment. We investigate the repeatability of WBMRI parameters using automatic disease delineation in APC patients.
This abstract and the presentation materials are available to members only; a login is required.